VC: Zogenix lands $60M in first round



Zogenix lands $60M in first round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Zogenix
San Diego

$60M
First

Clarus Ventures and Domain Associates

The company's initial focus is the completion of the late-stage development and commercialization of Intraject sumatriptan.

Codexis
Redwood City, CA

$37M
Fourth

Bio*One Capital

Much of the money will go to financing a new research and development arm in Singapore that will support its work in generics.

Medior
Malvern Hill, PA

$7M
First

Polaris Ventures and Morgenthaler Ventures

Medior is developing therapeutics for the treatment of fibrotic disorders and diseases.

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.